WO2002047647A1 - Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant - Google Patents
Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant Download PDFInfo
- Publication number
- WO2002047647A1 WO2002047647A1 PCT/FR2001/003633 FR0103633W WO0247647A1 WO 2002047647 A1 WO2002047647 A1 WO 2002047647A1 FR 0103633 W FR0103633 W FR 0103633W WO 0247647 A1 WO0247647 A1 WO 0247647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dhea
- composition according
- composition
- hydroxy
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/415—Aminophenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to a composition containing 7-hydroxy DHEA and / or 7-keto DHEA and at least one depigmenting agent, as well as to the use of said composition, in particular for preventing or treating the signs of skin aging actinic.
- DHEA dehydroepiandrosterone
- Exogenous DHEA administered topically or orally, is known for its ability to promote keratinization of the epidermis (JP-07
- 7 ⁇ -hydroxy DHEA is, with 5-androstene 3 ⁇ , 17 ⁇ -diol, a major metabolite of DHEA, obtained by the action of 7 ⁇ -hydroxylase on DHEA.
- minor metabolites of DHEA there may be mentioned 7 ⁇ -hydroxy DHEA, obtained by the action of 7 ⁇ -hydroxylase on DHEA and 7-keto DHEA, which is itself a metabolite of 7 ⁇ -hydroxy DHEA.
- the expression "7-hydroxy DHEA” will be used to denote either 7 ⁇ -hydroxy DHEA and 7 ⁇ -hydroxy DHEA.
- a subject of the present invention is therefore a composition containing, in a physiologically acceptable medium: (a) at least one DHEA derivative chosen from 7-hydroxy DHEA and 7-keto DHEA, and (b) at least one depigmenting agent.
- the 7-hydroxy DHEA is preferably 7 -OH DHEA.
- a process for the preparation of this compound is described in particular in patent applications FR-2 771 105 and WO 94/08588.
- 7 ⁇ -OH DHEA is also suitable for use in the present invention.
- the concentration of DHEA derivative in the composition according to the invention is advantageously between 0.0001% and 10% by weight, preferably between 0.001% and 5% by weight, relative to the total weight of the composition.
- composition according to the present invention contains, in association with the DHEA derivative, at least one depigmenting agent.
- the depigmenting agents which can be used according to the present invention are compounds which act directly on the vitality of the epidermal melanocytes in which melanogenesis takes place and / or interfere with one of the stages of melanin biosynthesis, either by inhibiting one of the enzymes involved in melanogenesis, either by intercalating as a structural analogue of one of the chemical compounds in the melanin synthesis chain, a chain which can then be blocked and thus ensure depigmentation.
- the depigmenting agent according to the invention is advantageously chosen from: DHEA; kojic acid; ellagic acid; arbutin and its derivatives such as those described in applications EP-895,779 and EP-524,109; hydroquinone; aminophenol derivatives such as those described in applications WO 99/10318 and WO 99/32077, and in particular N-cholesteryloxycarbonyl-para-aminophenol and N-ethyloxycarbonyl- para-aminophenol; iminophenol derivatives, in particular those described in the application.
- the depigmenting agent preferably represents from 0.01% to 5% and, better still, from 0.1% to 1% by weight, relative to the total weight of the composition.
- composition according to the invention is preferably suitable for topical application to the skin. It can be in all dosage forms normally used for this type of application, in particular in the form of an aqueous or oily solution, an oil-in-water or water-in-oil or multiple emulsion, a silicone emulsion, a microemulsion or nanoemulsion, an aqueous or oily gel or a liquid, pasty or solid anhydrous product.
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product.
- the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring materials.
- the amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase or into the aqueous phase.
- These adjuvants, as well as their concentrations must be such that they do not harm the advantageous properties of the DHEA derivatives, nor of the depigmenting agents according to the invention.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight, per relative to the total weight of the composition.
- the fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
- oils and in particular mineral oils such as mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin) can be used.
- synthetic oils perhydrosqualene
- silicone oils cyclomethicone
- fluorinated oils perfluoropolyethers.
- Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
- emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid esters of polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; fatty acid esters of polyols such as glyceryl stearate, sorbitan tristearate and the oxyethylenated sorbitan stearates available under the tradenames Tween ® 20 or Tween ® 60, for example; and their mixtures.
- polyethylene glycol such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate
- fatty acid esters of polyols such as glyceryl stearate, sorbitan tristearate and the oxyethylenated sorbitan stearates available under the tradenames Tween ® 20 or Tween ® 60, for example; and their mixtures.
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids and hydrophobic silica.
- composition according to the invention comprises an effective amount of DHEA derivative and an effective amount of depigmenting agent, sufficient to obtain the desired effect, in a physiologically acceptable medium.
- composition according to the invention finds particular application in the prevention and treatment of the signs of skin aging, in particular of actinic aging.
- the present invention therefore also relates to the cosmetic use of the composition mentioned above for preventing or treating the signs of skin aging, in particular of actinic aging.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002221995A AU2002221995A1 (en) | 2000-12-15 | 2001-11-20 | Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a depigmentation composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/16443 | 2000-12-15 | ||
FR0016443A FR2818138B1 (fr) | 2000-12-15 | 2000-12-15 | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002047647A1 true WO2002047647A1 (fr) | 2002-06-20 |
Family
ID=8857757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003633 WO2002047647A1 (fr) | 2000-12-15 | 2001-11-20 | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002221995A1 (fr) |
FR (1) | FR2818138B1 (fr) |
WO (1) | WO2002047647A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0723775A1 (fr) * | 1995-01-26 | 1996-07-31 | L'oreal | Utilisation du sulfate de déhydroépi-androstérone dans une composition cosmétique ou dermatologique |
WO1997003676A1 (fr) * | 1995-07-21 | 1997-02-06 | Cabo Soler Jose | Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee |
FR2771105A1 (fr) * | 1997-11-20 | 1999-05-21 | Vitasterol | Utilisation du fusarium monoliforme pour la preparation des derives 7alpha-hydroxyles de la dehydroepiandrosterone et de la pregnenolone |
-
2000
- 2000-12-15 FR FR0016443A patent/FR2818138B1/fr not_active Expired - Fee Related
-
2001
- 2001-11-20 WO PCT/FR2001/003633 patent/WO2002047647A1/fr not_active Application Discontinuation
- 2001-11-20 AU AU2002221995A patent/AU2002221995A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0723775A1 (fr) * | 1995-01-26 | 1996-07-31 | L'oreal | Utilisation du sulfate de déhydroépi-androstérone dans une composition cosmétique ou dermatologique |
WO1997003676A1 (fr) * | 1995-07-21 | 1997-02-06 | Cabo Soler Jose | Nouvelle formulation pharmaceutique de dehydroepiandrosterone pour application topique percutanee |
FR2771105A1 (fr) * | 1997-11-20 | 1999-05-21 | Vitasterol | Utilisation du fusarium monoliforme pour la preparation des derives 7alpha-hydroxyles de la dehydroepiandrosterone et de la pregnenolone |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Derwent World Patents Index; AN 1997-145203 * |
Also Published As
Publication number | Publication date |
---|---|
FR2818138A1 (fr) | 2002-06-21 |
AU2002221995A1 (en) | 2002-06-24 |
FR2818138B1 (fr) | 2003-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2312528C (fr) | Composition cosmetique raffermissante comprenant au moins un hydroxystilbene en association avec de l'acide ascorbique | |
EP1648569B1 (fr) | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite | |
FR2921255A1 (fr) | Utilisation d'un derive d'acide jasmonique a titre d'agent depigmentant | |
FR2784294A1 (fr) | Composition cosmetique et/ou dermatologique renfermant au moins un extrait de murier, au moins un extrait de scutellaire et au moins un derive d'acide salicylique | |
EP1343459B1 (fr) | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide | |
EP1172094B1 (fr) | Composition, notamment cosmétique, comprenant la DHEA et/ou un précurseur ou dérivé, et au moins un composé augmentant la synthèse des glycosaminoglycanes | |
CA2099473C (fr) | Composition cosmetique et/ou dermatologique a action depigmentante contenant un acide di- ou tri-cafeoylquinique ou un melange de ceux-ci | |
EP1303253B1 (fr) | Composition, notamment cosmetique, comprenant la dhea et/ou un precurseur ou derive de celle-ci, en association avec au moins un agent anti-glycation | |
EP0925779B1 (fr) | Composition cosmétique contenant de l'acide cinnamique ou d'au moins l'un de ses dérivés et son utilisation | |
EP1303250A1 (fr) | Composition, notamment cosmetique, renfermant la dhea et un isoflavono de | |
EP0602029A1 (fr) | Composition cosmetique ou pharmaceutique contenant un extrait de coleus esquirolii, de coleus scutellarioides ou de coleus xanthanthus. | |
EP1023894A1 (fr) | Composition cosmétique comprenant au moins un composé comportant un fragment phényloxime | |
WO2002047647A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant | |
WO2002047652A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent antimicrobien | |
WO2002047648A1 (fr) | Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent anti-glyction | |
WO2003011244A1 (fr) | Composition renfermant un steroide et un glycol | |
EP1343467A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un carotenoide | |
FR3142888A1 (fr) | Utilisation cosmétique d’une association d’acide salicylique et/ou de ses dérivés et/ou de leurs sels, de sarcosine et d’un extrait d’algue d’origine marine pour traiter et/ou prévenir les peaux grasses | |
WO2001026619A2 (fr) | Composition, notamment cosmetique, renfermant la dhea et un agent desquamant | |
WO2002005779A1 (fr) | Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et une vitamine | |
WO2002047645A1 (fr) | Composition renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent desquamant | |
FR2828400A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide | |
WO2002047655A1 (fr) | Composition, notamment cosmetique, comprenant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un inhibiteur de no-synthase | |
WO2003013466A1 (fr) | Composition comprenant une association de l'igf1 et au moins un isoflavonoide | |
FR2828401A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre l'igf1 et/ou un compose mimetique de l'igf1, et l'acide ascorbique et/ou au moins l'un de ses derives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |